Orbimed Advisors LLC Adverum Biotechnologies, Inc. Transaction History

Orbimed Advisors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$3.36 - $10.56 $18.5 Million - $58.1 Million	-5,501,144 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$9.84 - $14.26 $9.02 Million - $13.1 Million	916,800 Added 20.0%	5,501,144 $59.6 Million
Q3 2020 Nov 16, 2020	BUY	$10.3 - $21.64 $13.3 Million - $28 Million	1,293,600 Added 39.31%	4,584,344 $47.2 Million
Q2 2020 Aug 14, 2020	SELL	$8.53 - $25.64 $1.36 Million - $4.1 Million	-159,900 Reduced 4.63%	3,290,744 $68.7 Million
Q1 2020 May 15, 2020	SELL	$7.98 - $16.32 $7.11 Million - $14.6 Million	-891,546 Reduced 20.53%	3,450,644 $33.7 Million
Q4 2019 Feb 14, 2020	BUY	$5.12 - $12.22 $1.69 Million - $4.02 Million	329,221 Added 8.2%	4,342,190 $50 Million
Q3 2019 Nov 14, 2019	BUY	$5.24 - $15.89 $10.8 Million - $32.6 Million	2,052,769 Added 104.72%	4,012,969 $21.9 Million
Q2 2019 Aug 14, 2019	BUY	$5.1 - $11.89 $3.66 Million - $8.53 Million	717,000 Added 57.67%	1,960,200 $23.3 Million
Q1 2019 May 15, 2019	BUY	$3.03 - $6.02 $3.77 Million - $7.48 Million	1,243,200 New	1,243,200 $6.51 Million

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $467M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.